Form 4 Filing for Celldex Therapeutics, Inc. - Insider Transaction

This filing reports a transaction by Ronald Pepin, SR. VP & CBO of Celldex Therapeutics, Inc. On June 25, 2026, Pepin was granted 20,000 Incentive Stock Options to purchase the company's Common Stock at an exercise price of $34.09 per share. These options were granted under the 2021 Omnibus Equity Incentive Plan. The options have an exercise date of June 25, 2027, and an expiration date of June 25, 2036. Vesting begins with 25% on June 25, 2027, followed by quarterly vesting over the subsequent 12 quarters. Following this grant, Pepin holds 20,000 shares of Common Stock underlying these options.